Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia

被引:0
作者
Miggiano, MC
Gherlinzoni, F
Rosti, G
Bandini, G
Visani, G
Fiacchini, M
Ricci, P
Testoni, N
Motta, MR
Geromin, A
Rizzi, S
Belardinelli, A
Mangianti, S
Manfroi, S
Tura, S
机构
[1] POLICLIN S ORSOLA, INST HEMATOL SERAGNOLI, CTR TRASFUS, I-40136 BOLOGNA, ITALY
[2] UNIV UDINE, DIPARTIMENTO EMATOL, I-33100 UDINE, ITALY
关键词
autologous bone marrow transplantation; acute myelogenous leukemia; first complete remission; Bu/Cy protocol;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the role of ABMT in late 1st CR AML adult patients using busulfan plus cyclophosphamide as preparative regimen. Fifty-one adult patients (mean age 36 years, range 15-59) with AML underwent ABMT in 1st CR. Three of them had a prior diagnosis of myelodysplastic syndrome; one patient had a secondary leukemia. The median interval between CR and ABMT was 8 months (range 4-20). Patients received busulfan, 4 mg/kg/day for 4 days plus cyclophosphamide 50 mg/kg/day for 4 days or 60 mg/kg/day for 2 days. No maintenance chemotherapy was administered after ABMT. Median days to reach 0.5 x 10(9)/l PMN and 20 x 10(9)/l platelets were 26 (range 12-250) and 74 (range 16-740), respectively. No transplant-related deaths were observed. Five-year actuarial overall survival rate is 76.9%; actuarial leukemia-free survival rate is 70.6%. Mean follow-up from ABMT is 35 months. Leukemia-free survival of this group was compared with that of 38 non-transplanted patients younger than 60 years, who maintained a CR longer than 8 months in the same period. This analysis shows a statistically significant difference in favor of ABMT patients. These results suggest that, even if performed late after 1st CR as postremission intensification, ABMT can improve the outcome of AML patients.
引用
收藏
页码:402 / 409
页数:8
相关论文
共 40 条
  • [1] [Anonymous], 1989, Analysis of binary data
  • [2] APPELBAUM FR, 1988, BLOOD, V72, P179
  • [3] BAKER F, 1994, BONE MARROW TRANSPL, V13, P589
  • [4] BANDINI G, 1991, BRIT J HAEMATOL, V77, P486
  • [5] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
  • [6] BISHOP JF, 1990, BLOOD, V75, P27
  • [7] BOZZETTI F, 1990, MANUALE ONCOLOGIA ME, P1023
  • [8] Buchner T, 1990, Haematol Blood Transfus, V33, P261
  • [9] AUTOLOGOUS BONE-MARROW TRANSPLANT IN ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION
    CASSILETH, PA
    ANDERSEN, J
    LAZARUS, HM
    COLVIN, OM
    BENNETT, JM
    STADTMAUER, EA
    KAIZER, H
    WEINER, RS
    EDELSTEIN, M
    OKEN, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 314 - 319
  • [10] CHAO NJ, 1993, BLOOD, V81, P319